A Randomized, Double-blind, Parallel-group Study to Assess the Safety and Efficacy of Asacol (1.2 to 4.8g/Day) 400 mg Delayed-release Tablets Given Twice Daily for 26 Weeks to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis.

Trial Profile

A Randomized, Double-blind, Parallel-group Study to Assess the Safety and Efficacy of Asacol (1.2 to 4.8g/Day) 400 mg Delayed-release Tablets Given Twice Daily for 26 Weeks to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 24 May 2012

At a glance

  • Drugs Mesalazine (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms CAMP-III
  • Most Recent Events

    • 24 May 2012 Additional lead trial investigator (Herman Ellman) identified as reported by ClinicalTrials.gov.
    • 24 May 2012 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
    • 24 May 2012 Actual patient number is 39 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top